Clinical trials
Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 5,650 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06617416RecruitingPhase 3
AK104 for locally advanced lung cancer after chemoradiotherapy
This trial tests a new immunotherapy drug, AK104, for people with stage III non-small cell lung cancer that cannot be removed with surgery. It is for those who have finished chemoradiotherapy and have not gotten worse.
JinanAges 18 years+ - NCT06620835RecruitingPhase 2
Optimizing local treatments for ALK-positive lung cancer on brigatinib
This trial is for people with advanced ALK-positive lung cancer who are already taking the targeted therapy brigatinib and have a few remaining spots of cancer. It tests whether adding local treatments (like surgery, focused radiation, or ablation) to the remaining spots can improve outcomes.
BrestAges 18 years+ - NCT06652048RecruitingPhase 2
High-dose Furmonertinib for advanced lung cancer after progression
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06667908RecruitingPhase 2
Study of a drug with chemoradiation for stage 3 lung cancer
This trial tests a new drug, JNJ-90301900, given together with standard chemotherapy and radiation, followed by maintenance immunotherapy (durvalumab) for people with stage 3 non-small cell lung cancer that cannot be surgically removed. The goal is to see if adding this drug improves outcomes.
La Jolla, CaliforniaAges 18 years+ - NCT06896422RecruitingPhase 1
Testing glutathione with immunotherapy and chemo for lung cancer
This trial tests adding a supplement called glutathione to the usual immunotherapy (anti-PD-1) plus chemotherapy for advanced non-small cell lung cancer that has stopped responding to first treatment. It aims to see if this combination works better at shrinking tumors.
Zhengzhou, HenanAges 18 years+ - NCT06899789Recruiting
Long-term follow-up of colitis from checkpoint inhibitors
This study follows people who developed colitis (inflammation in the colon) after receiving immune checkpoint inhibitors for cancer. Researchers want to learn about long-term effects and outcomes.
Pavia, PaviaAges 18 years+ - NCT06956001RecruitingPhase 3
Testing firmanertinib vs chemo for first-line lung cancer with specific EGFR mutations
This trial compares a new targeted therapy pill (firmanertinib) to standard chemotherapy in people with advanced non-small cell lung cancer whose tumors have a specific EGFR mutation (PACC or L861Q). If you haven't had treatment for advanced disease and your cancer matches these mutations, this study may offer a more convenient oral option.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07008287Recruiting
Taletrectinib for ROS1+ lung cancer with brain spread
This study gathers real-world experience with the targeted drug taletrectinib for people with a specific type of advanced lung cancer (ROS1-positive) that has spread to the brain. Participation may help doctors better understand how well the drug works in everyday practice.
Hangzhou, ZhejiangAges 18 years+ - NCT07037680RecruitingPhase 2
Radiation plus Anlotinib for advanced lung cancer
This trial tests a combination of radiation therapy and a targeted drug (Anlotinib) for people with a type of advanced lung cancer that cannot be treated with standard chemoradiation. It may help if your cancer has not spread to other parts of the body and you have not had certain prior treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07046923RecruitingPhase 1
A study of LY4175408 for advanced cancer
This trial tests a new targeted drug (LY4175408) for people with certain advanced solid tumors (lung, endometrial, or triple negative breast cancer) who have already tried standard treatments. The goal is to see if the drug is safe and effective.
Stanford, CaliforniaAges 18 years+ - NCT07050043RecruitingPhase 3
Low-dose nivolumab plus chemo vs standard chemo for advanced lung cancer
This trial tests whether a lower dose of the immunotherapy drug nivolumab combined with standard chemotherapy works better than chemotherapy alone for people with advanced or metastatic non-small cell lung cancer (NSCLC) that has not been treated before.
Alor Star, KedahAges 18 years+ - NCT07070440RecruitingPhase 1/Phase 2
New combination therapy for advanced EGFR-mutated lung cancer
This trial tests a new combination therapy (DZD6008 plus other drugs) for people with advanced lung cancer that has an EGFR mutation and has stopped responding to a third-generation targeted therapy. It aims to find a better treatment option for these patients.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07079475RecruitingPhase 1/Phase 2
Study of two targeted pills for EGFR-mutated lung cancer
This trial tests a new combination of two oral targeted drugs for people with advanced non-small cell lung cancer that has an EGFR mutation. It may help if you have already been treated with a third-generation EGFR pill or if you are starting treatment for the first time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07086300Recruiting
Acupuncture with immunotherapy for older lung cancer patients
This trial tests whether adding electroacupuncture (a gentle, needle-based therapy) to a standard immunotherapy drug (PD-1 inhibitor) can help older adults with advanced lung cancer. It may improve treatment response and quality of life.
Tianjin, Tianjin MunicipalityAges 65–100 - NCT07132190RecruitingPhase 2
Radiation for growing brain tumors with same-day planning
This study tests whether a precise, one-day radiation treatment for brain tumors that are growing or in tricky spots can be effective with a smaller safety margin. It's designed for people whose brain tumors are changing quickly or sitting near areas of swelling or recent surgery.
Boston, MassachusettsAges 18 years+ - NCT07239661Recruiting
Acupuncture plus immunotherapy for advanced lung cancer
This trial tests whether adding electroacupuncture to a PD-1 inhibitor (a type of immunotherapy) can help people with advanced non-small cell lung cancer who have limited activity levels. It may improve treatment response and quality of life.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07348965Recruiting
High-dose furmonertinib for EGFR-mutant lung cancer that spread to the brain lining
This trial tests a new way to give a targeted therapy (furmonertinib) to people with a specific type of lung cancer that has spread to the lining of the brain. It uses a higher, pulsing dose to try to get more medicine into the brain fluid and stop the cancer there.
Guangzhou, GuangdongAges 18–75 - NCT07356544Recruiting
HER2 mutations in advanced non-small cell lung cancer
This study is looking at how common HER2 gene changes are in people with advanced non-small cell lung cancer (NSCLC) and how these changes affect treatment. By joining, you help researchers learn more about personalized care for this type of lung cancer.
Bari, BAAges 18 years+ - NCT07361705RecruitingPhase 1
Zorifertinib and osimertinib for lung cancer that spread to the brain lining
This trial tests a new drug, zorifertinib, combined with osimertinib for people whose lung cancer has spread to the lining of the brain (meninges) and continued to grow despite osimertinib treatment. The goal is to see if this combination can better control the brain spread.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07363811Recruiting
Nivolumab and immune cells in advanced lung cancer
This trial looks at the level of a specific type of immune cell (large granular lymphocytes) in people with advanced non-small cell lung cancer that has spread. It aims to see if these cells affect how well the drug nivolumab works. This could help doctors understand which patients benefit most from treatment.
Konya, MeramAges 18–90 - NCT07392658RecruitingPhase 2
Amivantamab plus chemo for EGFR-mutated lung cancer
This trial tests whether the drug amivantamab combined with a single chemotherapy drug can help people with advanced non-small cell lung cancer that has a specific EGFR gene mutation (exon20 insertion). It is for people who cannot safely receive standard platinum-based chemotherapy.
Roma, Roma (RM)Ages 18–99 - NCT02511288Recruiting
Blood tests to monitor advanced lung cancer during care
This study checks whether “liquid biopsies” (blood tests) can help monitor advanced non-small-cell lung cancer. It looks at different patient groups based on timing and tumor features, aiming to make cancer tracking easier and less invasive.
AnnecyAges 18 years+ - NCT07561723RecruitingPhase 1
IMP3 Vaccine for Advanced Lung Cancer After Treatment Failure
This study tests a new vaccine designed to help your immune system fight advanced lung cancer that has not responded to standard treatments. The vaccine targets a protein called IMP3 found in your cancer cells.
Chengdu, SichuanAges 18 years+ - NCT07647094RecruitingEarly Phase 1
Chemotherapy plus immunotherapy for advanced squamous lung cancer
This trial tests a combination of three drugs—two chemotherapy medications (carboplatin and nab-paclitaxel) plus an immunotherapy drug (serplulimab)—as a first-line treatment for advanced squamous cell non-small cell lung cancer. The goal is to see if this combination works better than standard treatment and is safe for patients who haven't received prior systemic cancer treatment.
Quzhou, ZhejiangAges 18–75
Hear when a new Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 5,650 recruiting advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.